top of page


Inhalon Biopharma is a clinical stage company focused on advancing a platform of inhaled 'muco-trapping' mAbs to treat various acute respiratory infections, transforming outpatient use of mAbs.

Inhalon rasied Series Seed in 2020 and Series A in 2022. It's technology and pipeline have been supported by over $45M in non-dilutive and dilutive funding.

bottom of page